Harry H. Qin, M.D., PhD, is the Chief Medical Officer at Aidea Pharma, a China-based biopharmaceutical focusing on R&D and commercialization of HIV care. Dr. Qin received his medical degree from Xi’an Jiaotong University College of Medicine, China, and his PhD in Gene, Cellular and Tissue Therapy from School of Medicine, King’s College, University of London, UK. He did his general surgery internship and pediatric and surgical oncology subspecialties residency in his home school affiliated hospitals, and completed his surgical research fellowship at David Geffen School of Medicine, University of California, Los Angeles, US. His research interests focuses on translational studies in cellular therapy for gastrointestinal diseases, especially congenital, and was awarded Young Investigator’s grants from European Association for the Study of the Liver and many other international medical and academic societies. He published more than ten peer-reviewed papers involving biomedical, translational and clinical researches in top journals like Lancet portfolio and cited by Nature portfolio papers. He started his industrial career at GlaxoSmithKline as a hepatitis medical officer. He has led dozens of clinical trials involving hepatitis B, C, NASH, and HIV across Asia Pacific. Theses trials have enabled regulatory approval and marketing of three new drugs in China.
